These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10563168)

  • 21. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rising prostate specific antigen after radical prostatectomy: a case based review.
    Nasr R; Goldenberg SL
    Can J Urol; 2001 Aug; 8(4):1306-13. PubMed ID: 11564273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
    Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
    Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New onset of heterophilic antibody interference in prostate-specific antigen measurement occurring during the period of post-prostatectomy prostate-specific antigen monitoring.
    Fritz BE; Hauke RJ; Stickle DF
    Ann Clin Biochem; 2009 May; 46(Pt 3):253-6. PubMed ID: 19264827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSA: prostate-specific antigen, persisting scientific ambiguities.
    Harv Mens Health Watch; 2009 Jul; 13(12):1-6. PubMed ID: 19718841
    [No Abstract]   [Full Text] [Related]  

  • 27. Relationship between prostate size and percent free prostate-specific antigen in patients with operable prostate cancer.
    Nativ O; Sabo E; Wald M; Halachmi S; Moskovitz B
    Isr Med Assoc J; 2000 Dec; 2(12):889-91. PubMed ID: 11344767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS; Sherin K;
    Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.
    Roehl KA; Eggener SE; Loeb S; Smith ND; Antenor JA; Catalona WJ
    Urol Oncol; 2006; 24(6):465-71. PubMed ID: 17138126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
    Ito K
    Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary view of prostate cancer diagnosis and treatment.
    Costello AJ
    Aust Fam Physician; 2003 Jun; 32(6):396-8. PubMed ID: 12833761
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 34. [Prostate cancer and prostate specific antigen screening].
    Camici M
    Minerva Med; 2004 Feb; 95(1):25-34. PubMed ID: 15041924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Early detection of cancer of the prostate. Pros and cons].
    Hoesl CE; Altwein JE
    MMW Fortschr Med; 2005 Apr; 147(14):32, 34-6. PubMed ID: 15887681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [PSA based screening for prostatic cancer].
    Johansen TE
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357
    [No Abstract]   [Full Text] [Related]  

  • 37. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Five-year results of prostate specific antigen (PSA) screening in Yokosuka City--comparative study between PSA-screened group and non-screened group].
    Noguchi S; Satomi Y; Sakai N; Takemura H; Ikeda S; Okui N; Kobayashi M; Fukuoka H; Furuhata A
    Hinyokika Kiyo; 2008 Mar; 54(3):197-201. PubMed ID: 18411775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.
    Isola J; Auvinen A; Poutiainen M; Kakkola L; Järvinen TA; Määttänen L; Stenman UH; Tammela T; Hakama M; Visakorpi T
    J Urol; 2001 May; 165(5):1569-74. PubMed ID: 11342919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The controversy over PSA testing: has anything changed?
    Johns Hopkins Med Lett Health After 50; 2009 Aug; 21(6):1-2. PubMed ID: 19722309
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.